Feasibility Trial of Methotrexate–Paclitaxel as a Second Line Therapy in Advanced Urothelial Cancer

REFERENCES

• Harker W.G., Meyers F.J., Freiha F.S., Palmer J.M., Shortliffe L.D., Hannigan J.F., McWhirter K.M., Torti F.M. Cisplatin, Methotrexate, and Vinblastine (CMV): An Effective Chemotherapy Regimen for Metastatic Transitional Cell Carcinoma of the Urinary Tract: A Northern California Oncology Group Study. J. Clin. Oncol. 1985; 3: 1463–1470
   PubMed Web of Science ®Google Scholar
• Sternberg C.N., Yagoda A., Scher H.I., Watson R.C., Herr H.W., Morse M.J., Sogani P.C., Vaughan E.D., Bander N., Weiselberg L.R. M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Advanced Transitional Cell Carcinoma of the Urothelium. J. Urol. 1988; 139: 461–469
   PubMed Web of Science ®Google Scholar
• Sternberg C.N., Yagoda A., Scher H.I., Watson R.C., Geller N., Herr H.W., Morse M.J., Sogani P.C., Vaughan K.D., Bander N. Methotrexate, Vinblastine, Doxorubicin, and Cisplatin for Advanced Transitional Cell Carcinoma of the Urothelium: Efficacy and Patterns of Response and Relapse. Cancer 1989; 64: 2448–2458
   PubMed Web of Science ®Google Scholar
• Bellmunt J., Ribas A., Eres N., Albanell J., Almanz C., Bermejo B., Sole L.A., Baselga J. Carboplatin Versus Cisplatin-Based Chemotherapy in the Treatment of Surgically Incurable Advanced Bladder Carcinoma. Cancer 1997; 80: 1966–1972
   PubMed Web of Science ®Google Scholar
• Loehrer P.J., Einhorn L.H., Elson P.J., Crawford E.D., Kubler P., Tannock I., Regharam D., Stuart-Harris R., Sarosdy M.F., Lowe B.A. A Randomized Comparison of Cisplatin Alone or in Combination with Methotrexate, Vinblastine, and Doxorubicin in Patients with Metastatic Urothelial Carcinoma: A Cooperative Group Study. J. Clin. Oncol. 1992; 10: 1066–1073
   PubMed Web of Science ®Google Scholar
• Logothetis C.J., Dexeus F.H., Finn L., Sella A., Amato R.J., Ayala A.G., Kilbourn R.G. A Prospective Randomized Trial Comparing MVAC and CISCA Chemotherapy for Patients with Metastatic Urothelial Tumors. J. Clin. Oncol. 1990; 8: 1050–1055
   PubMed Web of Science ®Google Scholar
• Seidman A.D., Scher H.I., Heinemann M.H., Bajorin D.F., Sternberg C.N., Dershaw D.D., Silverberg M., Bosl G.I. Continuous Infusion Gallium Nitrate for Patients with Advanced Refractory Urothelial Tract Tumors. Cancer 1991; 68: 2561–2565
   PubMed Web of Science ®Google Scholar
• Witte R.S., Elson P., Bono B., Knop R., Richardson R.R., Dreicer R., Loehrer PJ. Eastern Cooperative Oncology Group Phase II Trial of Ifosfamide in the Treatment of Previously Treated Advanced Urothelial Carcinoma. J. Clin. Oncol. 1997; 15(2)589–593
   PubMed Web of Science ®Google Scholar
• Witte R.S., Elson P., Khandaker J., Trump D.L. Eastern Cooperative Oncology Group Phase II Trial of Trimetrexate in Treatment of Advanced Urothelial Carcinoma. Cancer 1994; 73(3)688–691
   PubMed Web of Science ®Google Scholar
• Pollera C.F., Ceribelli A., Grecco M., Calabresi F. Weekly Gemcitabine in Advanced Bladder Cancer. A Preliminary Report from a Phase I Study. Ann. Oncol. 1994; 5: 182–184
   PubMed Web of Science ®Google Scholar
• Roth B., Dreicer R., Einhorn L.H., Neuberg D., Johnson D.H., Smith J.L., Hudes G.R., Schultz S.M., Loehrer P.J. Significant Activity of Paclitaxel in Advanced Transitional-Cell Carcinoma of the Urothelium: A Phase II Trial of the ECOG. J. Clin. Oncol. 1994; 12: 2264–2270
   PubMed Web of Science ®Google Scholar
• Edelman M.J., Meyers F., Houston J., Lauder I. Phase I Trial of Paclitaxel, Carboplatin and Methotrexate (MTX) with Granulocyte Colony-Stimulating Factor and Leucovorin in Advanced Transitional Cell Carcinoma. Semin. Oncol. 1997; 24(5 Suppl. 1)S15-68–S15-71
   Web of Science ®Google Scholar
• Bajorin D.F., McCaffrey J.A., Hilton S., Mazmudar M., Kelly W.K., Scher H.I., Spicer J., Herr H., Higgins G. Treatment of Patients with Transitional-Cell Carcinoma of the Urothelial Tract with Ifosfamide, Paclitaxel and Cisplatin: A Phase II Trial. J. Clin. Oncol. 1998; 16: 2722–2727
   PubMed Web of Science ®Google Scholar
• Redman B.G., Smith D.C., Flaherty L., Du W., Hussain M. Phase II Trial of Paclitaxel and Carboplatin in the Treatment of Advanced Urothelial Carcinoma. J. Clin. Oncol. 1998; 16: 1844–1848
   PubMed Web of Science ®Google Scholar
• Burch P.A., Richardson R.L., Cha S.S., Sargent D.J., Pitot H.C., Kaur J.S., Camoriano J.K. Phase II Study of Paclitaxel and Cisplatin for Advanced Urothelial Cancer. J. Urol. 2000; 164(5)1538–1542
   PubMed Web of Science ®Google Scholar
• Von der Maase H., Andersen L., Crino L., Weinknecht S., Dogliotti L. Weekly Gemcitabine and Cisplatin Combination Therapy in Patients with Transitional Cell Carcinoma of the Urothelium: A Phase II Clinical Trial. Ann. Oncol. 1999; 10: 1461–1465
   PubMed Web of Science ®Google Scholar
• Stadler W.M., Kuzel T., Roth B., Raghavan D., Dorr F.A. Phase II Study of Single-Agent Gemcitabine in Previously Untreated Patients with Metastatic Urothelial Cancer. J. Clin. Oncol. 1997; 15: 3441–3445
   PubMedGoogle Scholar
• Marini L., Sternberg C.N., Sella A., et al. A New Regimen of Gemcitabine and Paclitaxel in Previously Treated Patients with Advanced Transitional Cell Carcinoma. Proc. Am. Soc. Clin. Oncol. 1999; 18: 1335
   Google Scholar
• Meluch A.A., Greco F.A., Burris H.A., Hainsworth J.D. Gemcitabine and Paclitaxel Combination Therapy in Transitional Cell Carcinoma of the Urothelium. Eur. J. Cancer 2000; 36: S30–S33
   Web of Science ®Google Scholar
• Huber M.H., Lee J.S., Newman R.A., Fosella F.V., Wester M., Hong W.K., Lippman S.M. A Phase I Investigation of the Sequential Use of Methotrexate and Paclitaxel with and without G-CSF for the Treatment of Solid Tumors. Ann. Oncol. 1996; 7: 59–63
   PubMed Web of Science ®Google Scholar
• Fuchs D.A., Johnson R.K. Cytologic Evidence that Taxol, an Antineoplastic Agent from Taxus Brevifolia, Acts as a Mitotic Spindle Poison. Cancer Treat. Rep. 1978; 62: 1219–1222
   PubMedGoogle Scholar
• Niell H.B., Rangel C., Miller A., Cox C. The Activity of Antimicrotubular Agents in Human Bladder Tumor Cell Lines (HBTCL). Proc. Am. Assoc. Cancer Res. 1993; 34: 1025
   Google Scholar
• Rangel C., Niell H., Miller A., Cox C. Taxol and Taxotere in Bladder Cancer: In Vitro Activity and Urine Stability. Cancer Chemother. Pharmacol. 1994; 33: 460–464
   PubMed Web of Science ®Google Scholar
• Allegra C.J., Fine R.L., Drake J.C., Chabner B.A. The Effect of Methotrexate on Intracellular Folate Pools in Human MCF-7 Breast Cancer Cells: Evidence for Direct Inhibition of Purine Synthesis. J. Biol. Chem. 1986; 26: 6478–6485
   Google Scholar
• Fernandes D.J., Sur P., Kute T.E., Capizzi R.L. Proliferation-Dependent Cytotoxicity of Methotrexate in Murine L5718Y Leukemia. Cancer Res. 1988; 48: 5638–5644
   PubMed Web of Science ®Google Scholar
• Cos J., Bellmunt J., Soler C., Ribas A., Liuis J.M., Murio J.E., Margarit C. Comparative Study of Sequential Combinations of Paclitaxel and Methotrexate on a Human Bladder Cancer Cell Line. Cancer Investig. 2000; 18(5)429–435
   PubMed Web of Science ®Google Scholar
• Chou T.C. The Median Effect Principle and the Combination Index for Quantitation of Synergism and Antagonism. Synergism and Antagonism in Chemotherapy, T.C. Chou, D. Rideout. Academic Press, New York 1991; 62–89
   Google Scholar
• Dreicer R., Gustin D., See W.A., Williams R.D. Paclitaxel in Advanced Urothelial Carcinoma: Its Role in Patients with Renal Insufficiency and as Salvage Therapy. Proc. Am. Soc. Clin. Oncol. 1996; 15: 242–243, Abstract 607
   Google Scholar
• Gehan E.A. The Determination of the Number of Patients Required in a Preliminary and Follow-Up Trial of a New Chemotherapeutic Agent. J. Chronic Dis. 1961; 13: 346–353
   PubMedGoogle Scholar
• Kaplan E.L., Meier P. Nonparametric Estimation from Incomplete Observations. J. Am. Stat. Assoc. 1958; 53: 457–481
   Web of Science ®Google Scholar
• Kaufmann S.H., Peereboom D., Buckwalter C.A., Svingen P.A., Grochow L.B., Donehower R.C., Rowinsky E.K. Cytotoxic Effects of Topotecan Combined with Various Anticancer Agents in Human Cancer Cell Lines. J. Natl Cancer Inst. 1996; 88: 734–741
   PubMed Web of Science ®Google Scholar
• User's Guide. SAS, Cary, NC 1995
   Google Scholar
• Tu S.M., Hossan E., Amato R., Kilbourn R., Logothetis C.J. Paclitaxel, Cisplatin and Methotrexate Combination Chemotherapy is Active in the Treatment of Refractory Urothelial Malignancies. J. Urol. 1995; 154: 1719–1722
   PubMed Web of Science ®Google Scholar
• Otto T., Bex A., Krege S., Walz P.H., Rubben H. Paclitaxel-Based Second-Line Therapy for Patients with Advanced Chemotherapy-Resistant Bladder Carcinoma (M1): A Clinical Phase II Study. Cancer 1997; 80: 465–470
   PubMed Web of Science ®Google Scholar
• McCaffrey J.A., Hilton S., Mazumdar M., Sadan S., Kelly W.K., Scher H.L., Bajorin D.F. Phase II Trial of Docetaxel in Patients with Advanced or Metastatic Transitional Cell Carcinoma. J. Clin. Oncol. 1997; 15: 1853–1857
   PubMed Web of Science ®Google Scholar
• Chou T.C., Otter G.M., Sirotnak F.M. Combined Effects of Edatrexate with Taxol or Taxotere Against Breast Cancer Cell Growth. Proc. Am. Assoc. Cancer Res. 1993; 34: 300, Abstract 789
   Google Scholar
• Berenbaum M.C. What Is Synergy?. Pharmacol. Rev. 1989; 41: 93–141
   PubMed Web of Science ®Google Scholar
• Machado S.G., Robinson G.A. A Direct, General Approach Based on Isobolograms for Assessing the Joint Action of Drugs in Pre-Clinical Experiments. Stat. Med. 1994; 13: 2289–2309
   PubMed Web of Science ®Google Scholar
• Laska E.M., Meisner M., Tang D.I. Classification of the Effectiveness of Combination Treatments. Stat. Med. 1997; 16: 2211–2228
   PubMed Web of Science ®Google Scholar
• Chou T.C., Talalay P. Quantitative Analysis of Dose–Effect Relationships: The Combined Effects of Multiple Drugs or Enzyme Inhibitors. Adv. Enzyme Regul. 1987; 22: 27–55
   Google Scholar